In a nationwide study of Japanese hemodialysis patients, long-acting ESA use was associated with increased rates of cardiovascular and noncardiovascular mortality compared with short-acting ESA use.
The physician, who was experiencing an osteoarthritis flare following steroid therapy, began self-treating with turmeric extract capsules.
In a systematic review, not treating anemia in patients on dialysis turned out to be more costly than treatment with erythropoiesis-stimulating agents.
In a study, hepcidin and serum hsCRP predicted the erythropoietin resistance index in patients on hemodialysis.
Daprodustat maintained hemoglobin levels within a target range a majority of the time in patients with nondialysis chronic kidney disease and those on hemodialysis.
In 2 extension studies, molidustat appeared as effective as darbepoetin and epoetin in patients with non-dialysis chronic kidney disease or on hemodialysis patients.
The medication showed promise as correction and maintenance therapy in a phase 2b trial of non-dialysis CKD patients with anemia.
Study finds no decrease in the risk for mortality, myocardial infarction, or heart failure in the first 180 days.
Investigators found a U-shaped curve of mortality against ferritin/TSAT levels in patients without autosomal dominant polycystic kidney disease, but not in those with the disease.
Using statins for more than 3 months was significantly associated with 85% lower odds of ESA hyporesponsiveness in CKD patients.